Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favipiravir - FUJIFILM Toyama Chemical

Drug Profile

Favipiravir - FUJIFILM Toyama Chemical

Alternative Names: Avigan; T-705; T-705a

Latest Information Update: 05 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer BioDefense Therapeutics; FUJIFILM Holdings Corporation; FujiFilm Pharmaceuticals USA; FUJIFILM Toyama Chemical; Institut national de la sante et de la recherche medicale; MediVector; Toyama Chemical; Zhejiang Hisun Pharmaceutical
  • Class Amides; Antivirals; Pyrazines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections; Influenza virus infections
  • Phase III Viral infections
  • Phase II Ebola virus infections

Most Recent Events

  • 30 Jun 2020 Dr Reddy’s Laboratories and Global Response Aid in-licenses favipiravir from FUJIFILM to develop, manufacture and market in India, the Middle East, and other regions outside Japan
  • 30 Jun 2020 Updated efficacy data from a clinical trial in COVID-2019 infections released by Zhejiang Hisun Pharmaceutical
  • 29 Jun 2020 Launched for COVID-2019 infections in China (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top